



# Proteomics International

LABORATORIES LTD

ASX Release  
15 August 2022

ASX code: PIQ

## Proteomics International raises \$8m in highly successful Placement

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), a pioneer in predictive diagnostics, is pleased to advise that it has received firm commitments for a share placement to raise \$8 million (before costs) through the issue of 9.41 million shares in the Company (the "Placement").

The Placement was at an issue price of \$0.85 per share, a discount of 11.1% to the 5 day VWAP and was heavily oversubscribed, supported by Australian-based institutions, and sophisticated and professional investors.

Funds from the Placement (after costs) will be used for:

- Inventory build for the PromarkerD predictive test for diabetic kidney disease
- Implement US sales and marketing for PromarkerD
- Development of the Promarker™ diagnostics pipeline
- General working capital

Morgans Financial Limited acted as Lead Manager to the Placement, Euroz Hartleys Securities Limited acted as Co-Manager, and Candour Advisory acted as Corporate Advisor to the Placement.

Proteomics International Managing Director Dr Richard Lipscombe said we are delighted with the enormous level of support received both from new and existing investors, including Australian institutions.

*"Proteomics International has reached a major inflexion point in its corporate development - the route to commercialisation of the PromarkerD test in the United States is now clear [Proteomics International signs binding LOI with Sonic Healthcare USA, ASX: 9 August; 2 August] and we have exciting progress in our diagnostics pipeline as we advance towards potential new diagnostic tests for endometriosis [ASX: 1 August] and for oesophageal cancer [ASX: 21 June]. This substantial capital injection ensures our currently planned activities in these areas are fully funded, and I take this opportunity to thank existing shareholders for their continued support and to welcome new investors to the Proteomics International register."*

The shares under the Placement are expected to be issued on or around 22 August 2022 pursuant to the Company's 15% placement capacity under Listing Rule 7.1. Tranche 1 of the Placement (\$7.75m) is expected to settle on or around 19 August and, subject to shareholder approval, Proteomics International Directors Neville Gardiner, Paul House and Roger Moore will participate in Tranche 2 of the Placement (total \$0.25m).

Authorised by the Board Proteomics International Laboratories Ltd (ASX:PIQ).

ENDS

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

**About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

**About PromarkerD ([www.PromarkerD.com](http://www.PromarkerD.com))**

Diabetic kidney disease (DKD) is a serious complication arising from diabetes which if unchecked can lead to dialysis or kidney transplant. PromarkerD is a prognostic test that can predict future kidney function decline in patients with type 2 diabetes and no existing DKD. The patented PromarkerD test system uses a simple blood test to detect a unique ‘fingerprint’ of the early onset of the disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDL-cholesterol and estimated glomerular filtration rate (eGFR)). A cloud based algorithm integrates the results into a patient risk report. In clinical studies published in leading journals PromarkerD correctly predicted up to 86% of otherwise healthy diabetics who went on to develop diabetic kidney disease within four years. The PromarkerD test is CE Mark registered in the European Union.

Further information is available through the PromarkerD web portal.

To visit the PromarkerD virtual booth please see: [www.PromarkerD.com/product](http://www.PromarkerD.com/product)

**About the Promarker™ Platform**

Proteomics International's diagnostics development is made possible by the Company's proprietary biomarker discovery platform called Promarker, which searches for protein ‘fingerprints’ in a sample. This disruptive technology can identify proteins that distinguish between people who have a disease and people who do not, using only a simple blood test. It is a powerful alternative to genetic testing. The technology is so versatile it can be used to identify fingerprints from any biological source, from wheat seeds to human serum. The Promarker platform was previously used to develop PromarkerD, a world-first predictive test for diabetic kidney disease, that is currently being commercialised. Other tests in development include for asthma & COPD, oesophageal cancer, diabetic retinopathy and oxidative stress.

**For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Eliot Graham  
Manager, Corporate Advisory  
Morgans Financial Limited  
T: +61 3 9947 4101  
E: [eliot.graham@morgans.com.au](mailto:eliot.graham@morgans.com.au)

Dirk van Dissel  
Investor Relations & Corporate Advisor  
Candour Advisory  
T: +61 408 326 367  
E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

Kyle Moss  
Corporate Advisor  
Euroz Hartleys  
T: +61 8 9488 1400  
E: [kmoss@eurozhartleys.com](mailto:kmoss@eurozhartleys.com)

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)